Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised studyEribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study, Published online: 08 May 2019; doi:10.1038/s41416-019-0462-1Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Source: British Journal of Cancer - May 7, 2019 Category: Cancer & Oncology Authors: Jean-Yves Blay Patrick Sch öffski Sebastian Bauer Anders Krarup-Hansen Charlotte Benson David R. D ’Adamo Yan Jia Robert G. Maki Source Type: research